Table 2.

Detailed molecular mechanism of inhibition of Fas-induced cell killing.

	BCR	MHCII	CD19	CD40	IL-4	FDC	CpG
Fas expression	Unchanged/increased (Garrone et al., 1995; Rathmell et al., 1995; Rothstein et al., 1995; Foote et al., 1996b; Nakanishi et al., 1996; Bras et al., 1997; Schneider et al., 1997; Tumang et al., 2002; Schram and Rothstein, 2003; Moriyama and Yonehara, 2007) Decreased (Choe et al., 1996; Lagresle et al., 1996)	Not altered (Yoshino et al., 1995; Catlett et al., 2001; Blancheteau et al., 2002)	Not decreased (Barrington et al., 2005)/decreased (Mongini et al., 2003)	Upregulated (Garrone et al., 1995; Lagresle et al., 1995; Onel et al., 1995; Rathmell et al., 1995; Schattner et al., 1995; Wang et al., 1996)	Unchanged/increased (Foote et al., 1996a; Koizumi et al., 1996; Nakanishi et al., 1996; Wurster et al., 2002)	Upregulated (Tsunoda et al., 2000)	Decreased (Wang et al., 1997) Not decreased (Hancz et al., 2012)
DISC level	Reduced (Catlett and Bishop, 1999)/not changed (Carey et al., 2000; Wang et al., 2000) FADD association Reduced caspase-8 association (Wang et al., 2000) Reduced caspase-8 cleavage (Bras et al., 1997; Catlett and Bishop, 1999; Hinshaw et al., 2003; Moriyama and Yonehara, 2007) Transient upregulation of FLIP (Wang et al., 2000; Hennino et al., 2001; Owyang et al., 2001; Schram and Rothstein, 2003; Moriyama and Yonehara, 2007) FLIP silencing leads to Fas sensitivity (Moriyama and Yonehara, 2007) FLIP overexpression leads to resistance (Wang et al., 2000)	Reduced caspase-8 activity (Catlett et al., 2001) Elevated caspase-8 cleavage (Blancheteau et al., 2002)	Reduced caspase-8 cleavage (Mongini et al., 2003) Upregulation of FLIP (Mongini et al., 2003; Barrington et al., 2005)	Not changed Fadd association (Benson et al., 2006; Eeva et al., 2007) Decreased caspase-8 activation (Benson et al., 2006; Eeva et al., 2007) Flip expression is upregulated (Hennino et al., 2000, 2001; Eeva et al., 2007)		Reduced caspase-8 activity (van Eijk et al., 2001b) without FDC FLIP expression decays (Hennino et al., 2001) presence of FDC restore FLIP expression (van Eijk et al., 2001b)	Reduced caspase-8 activity (Hancz et al., 2012)
Mitochondria	Transient upregulation of Bcl-xl (Choe et al., 1996; Koizumi et al., 1996; Schneider et al., 1997; Owyang et al., 2001; Tumang et al., 2002; Schram and Rothstein, 2003) Bfl-1 upregulation (Tumang et al., 2002) Effective survival without upregulation of Bcl-xl (Alam et al., 1997; Owyang et al., 2001; Hinshaw et al., 2003; Moriyama and Yonehara, 2007) Overexpression of Bcl-xl does not display absolute survival (Schneider et al., 1997)		Upregulation of Bcl-2 (Mongini et al., 2003) Bcl-2 was not changed in (Barrington et al., 2005)	Bfl-1, A1, Bcl-xl upregulated (Lee et al., 1999)	Upregulated Bcl-xl (Wurster et al., 2002) marginal Bcl-xl upregulation (Schneider et al., 1997)	Bcl-2, Bcl-xl, Bax amount was unchanged (Schwarz et al., 1999; Tsunoda et al., 2000)
Other	Upregulation of FAIM, which results in the increase of FLIP expression (Schneider et al., 1999; Owyang et al., 2001; Huo et al., 2009)			Gadd45β upregulation (Zazzeroni et al., 2003)

Bold font, human; normal font, mouse.

Human: BCR (Garrone et al., 1995; Choe et al., 1996; Lagresle et al., 1996; Hennino et al., 2001; Alam et al., 1997), MHC (Yoshino et al., 1995; Blancheteau et al., 2002), CD19 (Mongini et al., 2003), CD40 (Garrone et al., 1995; Lagresle et al., 1995; Schattner et al., 1995; Benson et al., 2006; Hennino et al., 2000; Lee et al., 1999; Hennino et al., 2001), FDC (Tsunoda et al., 2000; van Eijk et al., 2001b; Hennino et al., 2001).